Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
Background. Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results. Patients and Methods. Analysis of consecutive patients with neuroendocrine carc...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1100/2012/170496 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555930229669888 |
|---|---|
| author | Ingrid H. Olsen Jens B. Sørensen Birgitte Federspiel Andreas Kjaer Carsten P. Hansen Ulrich Knigge Seppo W. Langer |
| author_facet | Ingrid H. Olsen Jens B. Sørensen Birgitte Federspiel Andreas Kjaer Carsten P. Hansen Ulrich Knigge Seppo W. Langer |
| author_sort | Ingrid H. Olsen |
| collection | DOAJ |
| description | Background. Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results. Patients and Methods. Analysis of consecutive patients with neuroendocrine carcinomas (Ki-67 proliferation index >20%) and performance status 0–2 treated with temozolomide 200 mg/sqm orally days 1–5 every 28 days after at least one previous platin-containing chemotherapy regimen. Results. Twenty-eight eligible patients received a median of 3 courses. Sixteen patients were evaluable for response: Six achieved stable disease and ten progressed. The median survival for the 28 patients was 3.5 months. Survival in patients with tumors of pancreatic origin (n=7) was 7.0 months versus 2.9 months in non-pancreatic origin (n=21). Patients in PS 0-1 (n=22) had a median survival of 4.5 months versus 1.1 months in patients in PS 2 (n=6). Ki-67 index ≥50% was associated with a significantly shorter median survival than Ki-67 index <50% (2.7 months versus 10.9 months). The treatment was well tolerated. Conclusion. Temozolomide monotherapy has limited effect in treatment of recurrent neuroendocrine carcinomas. Second line treatment with temozolomide in combination with other compounds should be further investigated in patients in good performance with Ki-67 index <50%. |
| format | Article |
| id | doaj-art-813cffaf14b2462099cd81b897c97ecf |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-813cffaf14b2462099cd81b897c97ecf2025-02-03T05:46:47ZengWileyThe Scientific World Journal1537-744X2012-01-01201210.1100/2012/170496170496Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine CarcinomasIngrid H. Olsen0Jens B. Sørensen1Birgitte Federspiel2Andreas Kjaer3Carsten P. Hansen4Ulrich Knigge5Seppo W. Langer6Department of Oncology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, DenmarkDepartment of Oncology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, DenmarkDepartment of Pathology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, DenmarkDepartment of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, DenmarkDepartment of Gastrointestinal Surgery C, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, DenmarkDepartment of Gastrointestinal Surgery C, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, DenmarkDepartment of Oncology, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, DenmarkBackground. Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results. Patients and Methods. Analysis of consecutive patients with neuroendocrine carcinomas (Ki-67 proliferation index >20%) and performance status 0–2 treated with temozolomide 200 mg/sqm orally days 1–5 every 28 days after at least one previous platin-containing chemotherapy regimen. Results. Twenty-eight eligible patients received a median of 3 courses. Sixteen patients were evaluable for response: Six achieved stable disease and ten progressed. The median survival for the 28 patients was 3.5 months. Survival in patients with tumors of pancreatic origin (n=7) was 7.0 months versus 2.9 months in non-pancreatic origin (n=21). Patients in PS 0-1 (n=22) had a median survival of 4.5 months versus 1.1 months in patients in PS 2 (n=6). Ki-67 index ≥50% was associated with a significantly shorter median survival than Ki-67 index <50% (2.7 months versus 10.9 months). The treatment was well tolerated. Conclusion. Temozolomide monotherapy has limited effect in treatment of recurrent neuroendocrine carcinomas. Second line treatment with temozolomide in combination with other compounds should be further investigated in patients in good performance with Ki-67 index <50%.http://dx.doi.org/10.1100/2012/170496 |
| spellingShingle | Ingrid H. Olsen Jens B. Sørensen Birgitte Federspiel Andreas Kjaer Carsten P. Hansen Ulrich Knigge Seppo W. Langer Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas The Scientific World Journal |
| title | Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas |
| title_full | Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas |
| title_fullStr | Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas |
| title_full_unstemmed | Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas |
| title_short | Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas |
| title_sort | temozolomide as second or third line treatment of patients with neuroendocrine carcinomas |
| url | http://dx.doi.org/10.1100/2012/170496 |
| work_keys_str_mv | AT ingridholsen temozolomideassecondorthirdlinetreatmentofpatientswithneuroendocrinecarcinomas AT jensbsørensen temozolomideassecondorthirdlinetreatmentofpatientswithneuroendocrinecarcinomas AT birgittefederspiel temozolomideassecondorthirdlinetreatmentofpatientswithneuroendocrinecarcinomas AT andreaskjaer temozolomideassecondorthirdlinetreatmentofpatientswithneuroendocrinecarcinomas AT carstenphansen temozolomideassecondorthirdlinetreatmentofpatientswithneuroendocrinecarcinomas AT ulrichknigge temozolomideassecondorthirdlinetreatmentofpatientswithneuroendocrinecarcinomas AT seppowlanger temozolomideassecondorthirdlinetreatmentofpatientswithneuroendocrinecarcinomas |